Clinical Trial Detail

NCT ID NCT02283658
Title Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

fallopian tube carcinoma

peritoneal carcinoma

ovarian carcinoma

Therapies

Everolimus + Letrozole

Age Groups: adult

No variant requirements are available.